Psilocybin for treating substance use disorders? - Test2 - elhamkhani - TriplyDB

Psilocybin for treating substance use disorders?

Psilocybin for treating substance use disorders?

http://www.wikidata.org/entity/Q38967632

about

Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance.Medications for alcohol use disorders: An overview.

P2860

Q39079288-5A63EDD2-972F-455A-9AB7-E17601DD9EBB Q47942161-02E96A56-4A16-4FA9-A272-6D100F7E257E

P2860

Psilocybin for treating substance use disorders?

http://www.wikidata.org/entity/Q38967632

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Psilocybin for treating substance use disorders?

@en

type

label

Psilocybin for treating substance use disorders?

@en

prefLabel

Psilocybin for treating substance use disorders?

@en

P1433

Q38967632-6BD61964-DF33-4EE1-9425-A5079B80CB2F

P1476

Q38967632-FB4F4A7C-2577-4408-AAFF-469AF1064967

P2093

Q38967632-4E711BCB-653B-475A-8B4B-0CA3231E4F61

Q38967632-4F2E760D-EF97-474F-AC57-7CD4F8A4CD82

Q38967632-81DA9917-B61E-48BC-A030-E2E63D913F97

P2860

Q38967632-01E7FA4D-F09B-426C-A1DF-81FD72F6DDB2

Q38967632-04F2EEBE-7378-4833-AE45-0739577F4732

Q38967632-0A63F077-4DA2-4364-AE95-1CA4AC40E6EE

Q38967632-0D0229D5-5525-4628-8C5C-8BF6F10128A8

Q38967632-1373AE4A-58C3-47C6-B0E0-208A728DE1BF

Q38967632-18C3D9D5-6841-4D98-851F-793F37C612EA

Q38967632-19AE7F1C-450F-45BD-8E1C-882A96180C03

Q38967632-1D5E18A3-0241-4D33-94C2-CD87C97DC2BE

Q38967632-2086A51E-479C-4CC1-BB21-D7282BC6FC67

Q38967632-219E29DB-B4CF-455E-A100-584AEAD783B6

P304

Q38967632-025E1A74-3B9C-477D-AAB5-BE4D61A91E6A

P31

Q38967632-86D8D36C-ADB3-4BDC-B395-C4F3BFAF5C76

P356

Q38967632-C8E17079-4E60-46CB-8104-81115AE8CF57

P433

Q38967632-D083F420-A236-411C-8CD4-FE3706B49D7A

P478

Q38967632-08811A15-AE4D-4FE6-A6E8-390614DCB9BC

P50

Q38967632-9105E59F-4734-4A0F-BA83-795216071A65

P577

Q38967632-76A9A95D-A201-4A1C-A842-315452A2D771

P698

Q38967632-9E82670D-95AA-4266-81E5-6541937748BF

P356

14737175.2016.1220834

P1433

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

P1476

Psilocybin for treating substance use disorders?

@en

P2093

Bas T H de Veen

http://www.w3.org/2001/XMLSchema#string

Judith R Homberg

http://www.w3.org/2001/XMLSchema#string

Michel M M Verheij

http://www.w3.org/2001/XMLSchema#string

P2860

Restructuring consciousness -the psychedelic state in light of integrated information theory

Prediction of psilocybin response in healthy volunteers

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

The neurobiology of psychedelic drugs: implications for the treatment of mood disorders

Development of cognitive control and executive functions from 4 to 13 years: evidence from manipulations of memory, inhibition, and task switching

Human hallucinogen research: guidelines for safety

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later

Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens.

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

P304

203-212

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737175.2016.1220834

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Arnt Schellekens

P577

2016-08-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27684102

http://www.w3.org/2001/XMLSchema#string